Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-aventis, Regeneron Expand Antibody Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Sanofi-aventis, Regeneron Expand Antibody Pact

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. entered into agreements to expand and extend their existing global collaboration established November 2007, to discover, develop, and commercialize therapeutic monoclonal antibodies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. entered into agreements to expand and extend their existing global collaboration established November 2007, to discover, develop, and commercialize therapeutic monoclonal antibodies.

Sanofi-aventis will increase its annual funding from $100million to $160 million beginning in 2010, and the research funding will extend through 2017. The companies plan to advance an average of four to five antibodies into clinical development each year. Sanofi-aventis has an option to extend the discovery program for an additional three years. Regeneron will contribute its VelocImmune technology to the collaboration and its next generation technologies for antibody generation.

“The first two years of our collaboration with sanofi-aventis have been extremely productive, with five VelocImmune human antibodies in or entering clinical development,” commented Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer of Regeneron. “The expansion of our collaboration provides even greater resources over a longer time horizon and will boost our efforts to build a deep pipeline of new human antibody product candidates. Sanofi-aventis is an ideal partner with the expertise and global reach to collaborate with us on our mission to bring important new medicines to patients around the world.”

“This collaboration expansion demonstrates sanofi-aventis’ commitment to become a key player in the field of monoclonal antibodies and our confidence in our partner Regeneron,” declared Marc Cluzel, executive vice president, R&D, sanofi-aventis. “It will further fuel our product pipeline and will allow us to bring multiple antibody product candidates into the clinic, thereby significantly increasing the chance of providing patients access to innovative drugs in various therapeutic areas.”

To date, the two companies have advanced four therapeutic antibodies into clinical development and have filed an IND for a fifth additional antibody.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters